EU MedTech Forum 2022: Regulatory Unpredictability Spurs Renewed Calls For Devices Agency
Executive Summary
In the EU, lack of regulatory predictability is creating frustration, sending innovators across the Atlantic, and has been a factor in calls for a devices agency. MedTech Europe’s Oliver Bisazza and BVMed’s Marc Pierre Möll reviewed the top concerns aired at the MedTech Forum in early May.
You may also be interested in...
Neovasc Plans ‘Two Shots On Goal’ For Reducer To Treat Angina
Neovasc’ COO Bill Little talked to Medtech Insight about the company’s plans to develop its Reducer transcatheter device to treat cardiac angina associated with or without obstructive coronary disease.
2023: A Bumpy Road Ahead For Implementation of Medtech Regulations
Originally intended to increase medical device safety, the EU’s medtech regulation is so hampered in its implementation that it is now arguably a bigger potential threat to patients than any of the scandals leading to its more stringent requirements.
Heads Of Medicines Agency Group Adds Another Authority Voice To Intense EU MDR Debate
EU member state authorities overseeing devices have been putting out a series of messages that promise action to ease the implementation chaos surrounding the EU’s new medtech regulations.